image credit- shutterstock
Sino Biological, Inc., based in China, has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Sino Biological's new Omicron product line includes recombinant Omicron Spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognizing the Omicron Spike protein, and the Omicron pseudovirus assay CRO service.
These reagents are critical and urgently needed research tools for scientists and researchers worldwide to understand the impact of the new Omicron mutations on viral transmission as well as therapeutic neutralizing antibody and prophylactic vaccine effectiveness.
Sino Biological CEO Dr. Jie Zhang stated, "With the state-of-the-art platform technology and expertise accumulated over a decade, in a race against time and the pandemic, we are very pleased to be able to produce the Omicron RBD protein in a new record of 6 days, spike binding antibody in 8 days, the spike-S1, S-ECD trimer proteins and pseudovirus in 10 days. We'll continue to monitor new mutations, and make sure we make research tools available to scientists as quickly as we possibly can."
